Orchestra BioMed, based in New Hope, is set to receive as much as $21 million in cash proceeds tied to Haemonetics Corporation’s acquisition of Ireland-based Vivasure.
Before the transaction closed on Jan. 9, 2026, Vivasure was a strategic holding of Orchestra BioMed.
The Bucks County biomedical innovation company, which specializes in accelerating high-impact technologies to patients through shared risk and reward partnerships, expects to receive $11 million of proceeds this year from the sale, made up of around $5 million upfront and $6 million tied to a first milestone payment.
Additional proceeds are expected in future periods through revenue earnouts that are linked to specific milestones.
Vivasure focuses on next-generation percutaneous vessel closure technology through its PerQseal Elite system, a sutureless and fully absorbable solution for structural heart and endovascular procedures.
The company filed a Premarket Approval application with the Food and Drug Administration in 2025 and has obtained CE Mark approval in Europe for both arterial and venous indications.
“Vivasure has been a strategic holding since the formation of Orchestra BioMed, and we have been active and intentional in supporting the company for many years,” said David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed.
Learn more about the New Hope biomedical innovation company at Orchestra BioMed.
_______
